These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27076630)

  • 1. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
    Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
    Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
    Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
    Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
    [No Abstract]   [Full Text] [Related]  

  • 4. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma.
    Gujar AD; Le S; Mao DD; Dadey DY; Turski A; Sasaki Y; Aum D; Luo J; Dahiya S; Yuan L; Rich KM; Milbrandt J; Hallahan DE; Yano H; Tran DD; Kim AH
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8247-E8256. PubMed ID: 27930300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.
    Menssen A; Hydbring P; Kapelle K; Vervoorts J; Diebold J; Lüscher B; Larsson LG; Hermeking H
    Proc Natl Acad Sci U S A; 2012 Jan; 109(4):E187-96. PubMed ID: 22190494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
    Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
    J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
    Ning JF; Stanciu M; Humphrey MR; Gorham J; Wakimoto H; Nishihara R; Lees J; Zou L; Martuza RL; Wakimoto H; Rabkin SD
    Nat Commun; 2019 Jul; 10(1):2910. PubMed ID: 31266951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
    Brandl L; Zhang Y; Kirstein N; Sendelhofert A; Boos SL; Jung P; Greten F; Rad R; Menssen A
    Neoplasia; 2019 Oct; 21(10):974-988. PubMed ID: 31442917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling.
    Yang C; Sudderth J; Dang T; Bachoo RM; McDonald JG; DeBerardinis RJ
    Cancer Res; 2009 Oct; 69(20):7986-93. PubMed ID: 19826036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
    Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myc/Mycn-mediated glycolysis enhances mouse spermatogonial stem cell self-renewal.
    Kanatsu-Shinohara M; Tanaka T; Ogonuki N; Ogura A; Morimoto H; Cheng PF; Eisenman RN; Trumpp A; Shinohara T
    Genes Dev; 2016 Dec; 30(23):2637-2648. PubMed ID: 28007786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma.
    Mair R; Wright AJ; Ros S; Hu DE; Booth T; Kreis F; Rao J; Watts C; Brindle KM
    Cancer Res; 2018 Sep; 78(18):5408-5418. PubMed ID: 30054337
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice.
    Huang CC; Wang SY; Lin LL; Wang PW; Chen TY; Hsu WM; Lin TK; Liou CW; Chuang JH
    Dis Model Mech; 2015 Oct; 8(10):1247-54. PubMed ID: 26398947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.
    Wang T; Liu L; Chen X; Shen Y; Lian G; Shah N; Davidoff AM; Yang J; Wang R
    Cell Death Dis; 2018 Feb; 9(2):220. PubMed ID: 29445162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the Nicotinamide Salvage Pathway as a New Toxification Route for Antimetabolites.
    Buonvicino D; Mazzola F; Zamporlini F; Resta F; Ranieri G; Camaioni E; Muzzi M; Zecchi R; Pieraccini G; Dölle C; Calamante M; Bartolucci G; Ziegler M; Stecca B; Raffaelli N; Chiarugi A
    Cell Chem Biol; 2018 Apr; 25(4):471-482.e7. PubMed ID: 29478906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.